Lisata Therapeutics, Inc. Overview
Pro stress-test →Lisata Therapeutics is a clinical-stage pharmaceutical company engaged in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product certepetide is in Phase 2 clinical studies for solid tumors including metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer.
Strategic Profile
Pro stress-test →The company's CendR Platform incorporates novel technologies to enable more effective tumor-targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors and can target immunosuppressive cells within the tumor to enable the patient's immune system and immunotherapies to fight cancer more effectively. Lisata has established partnerships including a global non-exclusive license agreement with Catalent to use certepetide as an SMARTag antibody-drug conjugate payload and a strategic alliance with GATC Health for AI-powered drug discovery.
Competitive Landscape
Pro stress-test →Lisata competes in the solid tumor oncology space with certepetide addressing multiple indications including pancreatic and gastrointestinal cancers. Direct competitors include other clinical-stage oncology companies targeting similar tumor types with peptide or immune-modulating approaches, along with established pharmaceutical players developing ADC platforms. The CendR Platform technology offers differentiation through enhanced drug penetration mechanisms.
Industry Context
Lisata Therapeutics, Inc. operates in Clinical-stage oncology therapeutics.
Key facts
Founded: 1980 · Headquarters: Basking Ridge, New Jersey · Employees: N/A · Revenue: N/A · Market cap: $17M